Work

First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.2564

Authors: Philippe L. Bedard, Michael A. Davies, Scott Kopetz, Keith T. Flaherty, Geoffrey Shapiro, Jason John Luke, Anna Spreafico, Bin Wu, Corinne Gomez, Sylvaine Cartot-Cotton, Florent Mazuir, Sandrine Micallef, Brigitte Demers, Dejan Juric

Institutions: Princess Margaret Cancer Centre, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, University of Chicago, Agios Pharmaceuticals (United States), Sanofi (France)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2922512710

Cites:

Cited by: 8

Related to: 10